第一款儿童生长激素缺乏症治疗长效制剂lonapegsomatropin-tcgd

Lonapegsomatropin-tcgd,the first long-acting new drug for the treatment of childhood growth hormone deficiency

lonapegsomatropin-tcgd(商品名:Skytrofa^(TM))是美国FDA批准的第1款用于儿童生长激素缺乏症治疗的长效制剂,可在1周内持续释放生长激素,每周仅需注射1次。与传统的每日注射生长激素疗法相比,lonapegsomatropin-tcpd可通过降低给药频次提升患者依从性,从而改善治疗效果。临床研究证实,与生长激素相比,每周1次的lonapegsomatropin-tcpd在第52周显示出更高的年化身高增长速率。本文就lonapegsomatropin-tcgd的作用机制、药动学、临床疗效、安全性、药物相互作用等方面进行述评。

Lonapegsomatropin-tcgd(tradename:Skytrofa^(TM))is the first long-acting new drug approved by FDA for the treatment of growth hormone deficiency in children.It can continuously release growth hormone and needs to be injected for only once a week.Lonapegsomatropin-tcpd improves patient compliance by reducing dosing frequency compared to traditional daily somatropin injection therapy.Clinical studies confirmed that weekly treatment of lonapegsomatropin-tcpd showed a higher annual growth velocity at week 52 compared with somatropin.In this article,the mechanism,pharmacokinetics,pharmacodynamics,clinical evaluation,safety,drug interaction and storage of lonapegsomatropin-tcpd are reviewed.